About: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2011 (uk) im September 2011 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q56620375-5040F732-FE74-40BE-944F-297C53B52A81
publication date	2011-09-08 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56620375-66369CCD-50E3-4ABF-B8D1-5B0636055B40
language of work or name	English
author name string	wds:Q56620375-0D955CD8-41E8-409F-8FA3-EAED347C2465 wds:Q56620375-12892796-A59C-46C7-AD91-B9AEAA093F28 wds:Q56620375-3247346F-A4C2-4884-85A4-7410825C93A5 wds:Q56620375-98D6E738-2768-41D1-B65E-365AD0FFF2C0 wds:Q56620375-C94127AD-4DE9-4180-8334-43B1F8275BA5 wds:Q56620375-DB39B4F9-CC77-4C9B-9572-A88C11C9E4CA wds:Q56620375-DEBDFA26-E515-468D-8A1A-F73A8A21FB4F
author name string	Werner Hacke Manesh R. Patel Scott D. Berkowitz Christopher C. Nessel Keith A.A. Fox Richard C. Becker John F. Paolini
rdfs:label	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (en) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (nl)
skos:prefLabel	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (en) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (nl)
name	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (en) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (nl)
author	wds:Q56620375-122C4638-092B-4680-B1F4-FA581E5A5842 wds:Q56620375-1AFE564B-6A03-42E4-AB77-7669B1092830 wds:Q56620375-63DC0FD1-584B-4B7D-8E9E-0BDEBC6C80B8 wds:Q56620375-77F19682-92E0-4A4F-A526-7E8A1842E6A5 wds:Q56620375-A3353339-34E9-4AD8-8A1D-0E5D79BA7975 wds:Q56620375-B6266660-8206-4863-AD60-6790C9B6EF63 wds:Q56620375-CD142F84-BDE3-4588-8609-D544959CBB74 wds:Q56620375-EEABA174-139B-4EFC-AB38-ADD08E1D0F9E wds:Q56620375-F1DEDF68-C16B-4EB1-A891-2AF4EEF5303C
author	Robert Califf Jonathan L. Halperin Günter Breithardt Jonathan P Piccini Daniel E. Singer Kenneth W Mahaffey Graeme J. Hankey Jyotsna Garg Guohua Pan
title	wds:Q56620375-55DF8B78-3107-41F7-928B-0AA46B87D1EE
title	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (en)
page(s)	wds:Q56620375-5CBFB272-E25C-4EE1-B909-473847AC4644
page(s)	883-891
instance of	wds:Q56620375-E09C08B1-0B66-4565-A99B-018A44456CD0
instance of	scholarly article
main subject	wds:Q56620375-440FF24C-3AD5-4488-B553-612E97E80469 wds:Q56620375-61C0B9D3-8665-4321-88D8-818839C19E86
main subject	(RS)-warfarin atrial fibrillation
PubMed ID	wds:Q56620375-3AF2CDBA-5132-4D56-B1DF-CE2CC4BBA83B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21830957
PubMed ID	21830957
published in	wds:Q56620375-F4418006-CC49-49DE-9299-BE28BB03141E
published in	The New England Journal of Medicine
issue	wds:Q56620375-A3FFEF6F-0926-4183-A53E-EA3E64A076C3
volume	wds:Q56620375-33DD9A3D-6B8A-4D91-895E-24F8727E4303
issue	10
volume	365
DOI	wds:Q56620375-D3992E05-0785-4D27-A2CD-52220D4E56EE
DOI	http://dx.doi.org/10.1056/NEJMOA1009638%23T%3DARTICLE
DOI	10.1056/NEJMOA1009638#T=ARTICLE
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56620375
is cites work of	Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH Beyond warfarin: The advent of new oral anticoagulants A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands Recent trends in cost-related medication nonadherence among stroke survivors in the United States Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation Transitions of care in anticoagulated patients Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). [Primary and secondary prevention of stroke].

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software